spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  XTANDI  

 HSMN NewsFeed - 22 Mar 2024
Astellas Receives Positive CHMP Opinion for XTANDI(TM) in Additional Recurrent Early Prostate Cancer Treatment Setting
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 4 May 2021
Astellas' XTANDI(TM) (enzalutamide) Approved by European Commission for Men with Metastatic Hormone-Sensitive Prostate Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 6 Nov 2020
XTANDI(R) (enzalutamide soft capsules) Approved by China NMPA for the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 29 May 2020
XTANDI(R) (enzalutamide) Approved by Japan MHLW for the Treatment of Prostate Cancer with Distant Metastasis
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 14 Sep 2017
Pfizer and Astellas Announce Positive Top-Line Results from Phase 3 PROSPER Trial of XTANDI (enzalutamide) in Patients with Non-Metastatic Castration-Resistant Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Sep 2016
Pfizer Completes Acquisition of Medivation
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 22 Aug 2016
Pfizer to Acquire Medivation
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 24 Mar 2016
Pivotal Phase III Trial of enzalutamide Initiated in Metastatic Hormone Sensitive Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Apr 2014
Astellas Announces European Regulatory Submission For XTANDI(R) (enzalutamide) Capsules For Chemotherapy-Naive Metastatic Prostate Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 24 Jun 2013
XTANDI(TM) (Enzalutamide) Authorized in the European Union for Advanced Prostate Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 5 Jun 2013
Astellas Signs Distribution Agreement With Tecnofarma For Enzalutamide In Latin America
Biopharmaceuticals Distribution
 HSMN NewsFeed - 24 May 2013
Astellas and Medivation Announce Submission of Application for Marketing Approval of Enzalutamide, an Oral Androgen Receptor Inhibitor, in Japan
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 15 May 2013
Tokai Pharmaceuticals Announces $35.5 Million Series E Financing
Biopharmaceuticals Oncology Venture Capital
Return to NewsFeed  
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.